Meeting
2016 ASCO Annual Meeting
Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).
Authors
Daniel Peter Petrylak
Yale University, New Haven, CT
Daniel Peter Petrylak , Elisabeth I. Heath , Guru Sonpavde , Saby George , Alicia Katherine Morgans , Bernhard J. Eigl , Joel Picus , Susanna Y. Cheng , Sebastien J. Hotte , Elaina M. Gartner , Martha Vincent , Rong Chu , Banmeet Anand , Karen Morrison , Lynnae Jackson , Leonard M. Reyno , Evan Y. Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT01963052
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4532)
DOI
10.1200/JCO.2016.34.15_suppl.4532
Abstract #
4532
Poster Bd #
155
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).
First Author: Jonathan E. Rosenberg
Poster
2017 ASCO Annual Meeting
A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors.
First Author: Markus Joerger
First Author: Mark T. Fleming
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC).
First Author: Ding-Wei Ye